A study analysing effectiveness and safety of systematic non-medical switching from originator adalimumab to ADA ABP501
Latest Information Update: 10 Jan 2022
At a glance
- Drugs Adalimumab (Primary)
- Indications Axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 10 Jan 2022 New trial record